Top Page
Healius Limited
(Sydney:HLS)
Healius Limited (HLS) vs. iShares MSCI Australia ETF (EWA)
Healius Limited Business Overview & Revenue Model
Healius Limited Financial Statement Overview
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 1.56B | 1.75B | 1.71B | 2.29B | 1.90B | 1.56B | Gross Profit |
| 461.90M | 1.52B | 341.70M | 779.20M | 526.50M | 343.60M | EBIT |
| 408.60M | 65.50M | 94.90M | 474.10M | 255.40M | 86.10M | EBITDA |
| 77.80M | -298.10M | -57.80M | 734.80M | 470.40M | 300.80M | Net Income Common Stockholders |
| -22.80M | -645.80M | -374.60M | 307.90M | 43.70M | -70.50M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 85.70M | 60.10M | 115.30M | 81.30M | 70.10M | 137.50M | Total Assets |
| 3.02B | 2.98B | 3.65B | 4.14B | 3.78B | 4.59B | Total Debt |
| 1.62B | 1.60B | 1.77B | 1.78B | 1.44B | 1.75B | Net Debt |
| 1.53B | 1.54B | 1.65B | 1.70B | 1.37B | 1.61B | Total Liabilities |
| 1.97B | 1.94B | 2.15B | 2.22B | 1.92B | 2.66B | Stockholders Equity |
| 1.05B | 1.04B | 1.51B | 1.92B | 1.86B | 1.93B |
| Cash Flow | Free Cash Flow | ||||
| 292.70M | 173.80M | 230.30M | 480.30M | 432.00M | 307.80M | Operating Cash Flow |
| 338.50M | 237.80M | 306.40M | 573.80M | 493.30M | 380.20M | Investing Cash Flow |
| -56.50M | -63.00M | 67.30M | -401.70M | 386.90M | -121.90M | Financing Cash Flow |
| -251.40M | -259.00M | -339.70M | -163.50M | -952.10M | -233.60M |
Healius Limited Technical Analysis
Healius Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $5.25B | 3.24 | -45.38% | 2.81% | 16.79% | -0.06% | |
45 Neutral | €628.10M | ― | -4.46% | ― | -7.82% | 98.08% | |
| $2.96B | 22.01 | 6.45% | 2.46% | ― | ― | ||
| $11.50B | 47.35 | 20.61% | 1.58% | ― | ― | ||
| $5.62B | 1,000.00 | 0.52% | 2.40% | ― | ― | ||
70 Outperform | AU$12.74B | 23.29 | 6.86% | 4.03% | 10.15% | 6.20% |
Healius Limited Corporate Events
Healius Limited announced that Perpetual Limited and its related bodies corporate have ceased to be substantial holders in the company as of May 27, 2025. This change in shareholding could impact Healius’s market dynamics and stakeholder relationships, as substantial holders often influence company decisions and strategic directions.
The most recent analyst rating on (AU:HLS) stock is a Hold with a A$1.65 price target. To see the full list of analyst forecasts on Healius Limited stock, see the AU:HLS Stock Forecast page.
Healius Limited has announced the appointment of Kylie Brown as a Company Secretary, effective 29 May 2025. This strategic appointment, alongside the continued service of Stephen Humphries and Gillian Nairn in their respective roles, reinforces Healius’s commitment to maintaining robust communication and compliance with ASX Listing Rules, potentially enhancing its operational efficiency and stakeholder confidence.
The most recent analyst rating on (AU:HLS) stock is a Hold with a A$1.65 price target. To see the full list of analyst forecasts on Healius Limited stock, see the AU:HLS Stock Forecast page.
Healius Limited has announced a change in the interests of a substantial holder, with State Street Corporation and its subsidiaries adjusting their voting power in the company. This update reflects the dynamic nature of shareholder interests and could influence the company’s governance and decision-making processes.
The most recent analyst rating on (AU:HLS) stock is a Hold with a A$1.65 price target. To see the full list of analyst forecasts on Healius Limited stock, see the AU:HLS Stock Forecast page.
Healius Limited has experienced a change in the interests of its substantial holder, Spheria Asset Management Pty Ltd, which has decreased its voting power from 8.59% to 7.34%. This change reflects a reduction in the number of shares held by Spheria, impacting the company’s shareholder dynamics and potentially influencing future decision-making processes within Healius.
Healius Limited has announced a new dividend distribution for its shareholders, with a distribution amount of AUD 0.413 per share. The ex-date for the dividend is set for May 9, 2025, with a record date of May 12, 2025, and payment scheduled for May 23, 2025. This announcement reflects Healius Limited’s ongoing commitment to delivering value to its shareholders and may positively impact its market positioning by reinforcing investor confidence.
Healius Limited has announced a fully franked special dividend of 41.3 cents per share, amounting to approximately $300 million, with key dates set for May 2025. Additionally, the company has secured a new $300 million syndicated bank facility to replace its existing $680 million facility, aiming to be in a net cash position by the end of the fiscal year, reflecting a strategic move to optimize financial operations and maintain industry competitiveness.
Healius Limited has completed the sale of Lumus Imaging to Affinity Equity Partners for $822 million, allowing Healius to focus on its pathology strategy and streamline operations. The transaction will enable Healius to pay a special dividend and provide transitional services to Lumus Imaging for up to eighteen months, ensuring a smooth transition for both the company and its patients.
Healius Limited has announced changes to the employment terms of its CEO, Paul Anderson, transitioning his role to permanent ongoing employment and increasing his fixed annual remuneration. The CEO’s incentive arrangements for FY27 will align with other key management personnel, including short-term and long-term incentives, reflecting a strategic move to enhance leadership stability and align executive compensation with company performance goals.
Healius Limited has announced the unconditional sale of its Lumus Imaging division to Affinity Equity Partners, with the completion date set for May 1, 2025. This strategic move, following the fulfillment of all conditions including regulatory approvals, is expected to impact Healius’s operations by allowing it to focus more on its core diagnostics services, potentially enhancing its market positioning and value for stakeholders.
Healius Limited announced the details of its Investor Day, which took place on March 27, 2025, both via webcast and in-person at UBS in Sydney. The event faced a minor issue with webcast registration confirmations, which omitted the webcast link, highlighting the company’s commitment to transparency and stakeholder engagement.
Healius Limited held its Investor Day 2025, focusing on its financial results and business prospects. The presentation included forward-looking statements, highlighting potential risks and uncertainties such as regulatory decisions, competitive changes, and cost fluctuations that could impact the company’s future outcomes.
Perpetual Limited has reduced its substantial holding in Healius Limited from 9.785% to 8.784%, reflecting a decrease in voting power. This change in shareholding may impact Healius’ market dynamics and influence stakeholder perceptions, as substantial holders play a significant role in company governance and strategic decisions.